Current Report Filing (8-k)
06 November 2018 - 1:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 5, 2018
IMPRIMIS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35814
|
|
45-0567010
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
12264
El Camino Real, Suite 350
|
|
|
San
Diego, CA
|
|
92130
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 704-4040
N/A
(Former name or former address if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.02
|
|
Termination
of a Material Definitive Agreement.
|
On
November 5, 2018, Imprimis Pharmaceuticals, Inc. (the “Company”) provided notice of termination to Cantor
Fitzgerald & Co. (“Cantor”) of the Controlled Equity Offering
SM
Sales Agreement, dated November
27, 2015 (the “Sales Agreement”), by and between the Company and Cantor. The termination will become effective on
November 15, 2018, following a ten-day notice period pursuant to Section 13(b) of the Sales Agreement.
The
Company is terminating the Sales Agreement because it estimates that cash flow provided by operations will be sufficient to fund
its operating expenses, capital expenditures and working capital requirements for at least the next twelve (12) months, and it
will not need to sell its common stock through the Sales Agreement to fund its planned level of operations.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMPRIMIS
PHARMACEUTICALS, INC.
|
|
|
|
Dated:
November 6, 2018
|
By:
|
/s/
Andrew R. Boll
|
|
Name:
|
Andrew
R. Boll
|
|
Title:
|
Chief
Financial Officer
|
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ): 0 Nachrichtenartikel
Weitere Imprimis Pharmaceuticals, Inc. News-Artikel